Finance Watch: Blackstone Closes $1.6bn Fund To Back Commercial-Stage Companies
Follow-On To $4.6bn Fund Raised In 2020
Public Company Edition: Blackstone Life Sciences Yield will finance approved products, while the firm’s prior fund supports late-stage programs. Also, Coeptis will merge with a SPAC, Bausch + Lomb secured post-IPO debt, and BioXcel revealed a $260m financing and new subsidiary.
